We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+56.71%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$12.1M
Cap. Flow
+$13.4M
Cap. Flow %
7.43%
Top 10 Hldgs %
65.55%
Holding
34
New
12
Increased
4
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.8M
2
CGON icon
CG Oncology
CGON
+$13.1M
3
VRNA
Verona Pharma
VRNA
+$12.7M
4
RAPT
RAPT Therapeutics
RAPT
+$7.3M
5
KURA icon
Kura Oncology
KURA
+$7.1M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$13.3M
2
CBAY
Cymabay Therapeutics
CBAY
+$11.6M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$8.98M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 98.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$12.4B
– –
-100,862
Closed -$8.03M
CMPX icon
27
Compass Therapeutics
CMPX
$373M
– –
-834,630
Closed -$1.3M
MLTX icon
28
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-143,479
Closed -$8.66M
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-141,348
Closed -$10.1M
ALPN
30
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-357,271
Closed -$6.81M
CBAY
31
DELISTED
Cymabay Therapeutics
CBAY
– –
-489,938
Closed -$11.6M
AMAM
32
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-385,383
Closed -$5.49M
MDVL
33
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
– –
-117,897
Closed -$529K
HARP
34
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-428,400
Closed -$4.87M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q1 2024 Portfolio in Review

As of Q1 2024, Ally Bridge Group held 34 positions worth $180M, up 7.2% from $168M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Ally Bridge Group deployed $13.4M of net new capital in Q1 2024, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was Blueprint Medicines: 160,950 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Jasper Therapeutics, an estimated $1.35M trimmed.

  • Ally Bridge Group's largest Q1 2024 buy was Blueprint Medicines: 160,950 shares worth $15.3M.
  • Ally Bridge Group added most to Praxis Precision Medicines in Q1 2024, an estimated $4M increase.
  • Ally Bridge Group's biggest Q1 2024 reduction was Jasper Therapeutics, cutting an estimated $1.35M.
  • Ally Bridge Group fully exited argenx in Q1 2024, selling an estimated $13.3M.
  • Ally Bridge Group's ten largest holdings make up 66% of its $180M portfolio in Q1 2024.
  • Ally Bridge Group opened 12 new positions and closed 12 in Q1 2024.
  • Ally Bridge Group's portfolio value rose 7.2% quarter-over-quarter to $180M.

Based on Ally Bridge Group's 13F filing for Q1 2024, filed 15 May 2024.